MedTrace Logo

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

NCT05043506 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1939

Last updated 2024-03-27

No results posted yet for this study

Summary

A retrospective observational analysis of de-identified data from a multinational medical record review to describe patient characteristics, treatment patterns, and effectiveness of palbociclib + AI as first-line therapy among adult patients with HR+/HER2- advanced breast cancer (ABC) in Europe

Conditions

Interventions

DRUG

Palbociclib + aromatase inhibitor

Palbociclib + an aromatase inhibitor therapy

DRUG

Aromatase inhibitor

Aromatase inhibitor monotherapy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-08
Primary Completion
2023-11-02
Completion
2023-11-02
FDA Drug
Yes

Countries

  • Austria
  • Belgium
  • Germany
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043506 on ClinicalTrials.gov